Prognostic
Revolutionizing prognostic testing with advanced precision and personalized approaches
At Castle Biosciences, we believe that each patient's journey is unique. Prognostic testing provides information about the future course of the patient's disease, which can help clinicians tailor treatment plans and interventions to improve health outcomes. Our prognostic tests go beyond traditional diagnostic approaches, providing physicians with a comprehensive understanding of disease aggressiveness, recurrence risk and treatment response.
DecisionDx-Melanoma
Provides comprehensive, personalized, genomic tumor information to guide management for patients with cutaneous melanoma
DecisionDx-SCC
Identifies the risk of metastasis in patients with squamous cell carcinoma (SCC) and one or more risk factors
DecisionDx-UM
Provides comprehensive profiling for evaluating metastatic risk in uveal melanoma
TissueCypher
Predicts individual risk of progression to esophageal cancer in Barrett’s esophagus